Description: Solid Biosciences Inc is a life science company engaged in developing therapies for Duchenne muscular dystrophy. Its product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles.
Home Page: www.solidbio.com
SLDB Technical Analysis
141 Portland Street
Cambridge,
MA
02139
United States
Phone:
617 337 4680
Officers
| Name | Title |
|---|---|
| Mr. Ian F. Smith A.C.A., ACA, C.P.A., CPA | Exec. Chair |
| Mr. Ilan Ganot | Co-founder, Strategic Advisor to the CEO & Director |
| Mr. Matthew Bennett Arnold | Co-Founder & Board Member |
| Mr. Alexander G. Cumbo | Pres, CEO & Director |
| Mr. Gilad David Hayeem | Co-Founder |
| Ms. Annie Ganot | Co-Founder & Head of Patient Advocacy |
| Dr. Andrey Juan Zarur Ph.D. | Co-Founder |
| Mr. Stephen J. Di Palma M.B.A, M.B.A. | Interim CFO, Treasurer & Principal Accounting Officer |
| Mr. Paul Herzich | Chief Technology Officer |
| Mr. David Tyronne Howton Jr., J.D. | Chief Admin. Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9036 |
| Price-to-Sales TTM: | 11.8924 |
| IPO Date: | 2018-01-26 |
| Fiscal Year End: | December |
| Full Time Employees: | 104 |